Investment in the Disposable Orthokeratology Business Using Euro-Yen Convertible Bonds Due 2025
First written in FY2021-Q3. 16 of 17 entries say "Advanced", first in FY2021. Latest entry: 2026-08-07.
22 other companies' latest entry also says "Advanced".
- 2026-08-07AdvancedFinancial Results Presentation
「マレーシア工場を中心に、生産能力強化を進める」
マレーシア・各務原・シンガポールの工場を示し、1DAYの供給能力強化を継続している。 - FY2026AdvancedAnnual report
「During the fiscal year, the Malaysia plant began commercial production. The company will continue expanding production capacity for these lenses and working to increase sales of daily disposable contact lenses globally, including in Japan.」
With regard to expanding daily disposable lens supply capacity, the company reached the key milestone of beginning commercial production at the Malaysia plant. The equipment plan also continues to include the addition of 8 production lines at the plant. - FY2025AdvancedAnnual report
「The total was ¥16,601 million, centered on the establishment of a plant at Menicon Malaysia Sdn. Bhd. and the expansion of production facilities at メニコンネクト, the Kakamigahara plant and Menicon Singapore.」
¥16,601 million was invested in the Malaysia, Kakamigahara and Singapore plants and elsewhere to expand supply capacity for daily disposable lenses and care products. The equipment plan calls for 8 production lines at the Malaysia plant, scheduled for completion in December 2027. - FY2025-H1AdvancedAnnual report
「Current assets decreased by ¥4,834 million to ¥80,936 million, mainly because cash and deposits declined as payments were made for manufacturing equipment related to the construction of a daily disposable contact lens manufacturing plant at Menicon Malaysia Sdn. Bhd. and for care product manufacturing equipment at メニコンネクト. Property, plant and equipment increased by ¥8,355 million to ¥102,395 million, mainly due to capital expenditures at Menicon Malaysia Sdn. Bhd.」
Investment in the Menicon Malaysia daily disposable lens manufacturing plant and メニコンネクト care product equipment progressed, increasing property, plant and equipment by ¥8,355 million from the end of the previous fiscal year. - FY2024AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year were mainly directed toward expanding facilities to accommodate increased production volumes of daily disposable contact lenses and care products. Total capital expenditures for the consolidated fiscal year were ¥24,229 million, of which ¥23,531 million was in the vision care business, mainly for establishing the Menicon Malaysia plant and expanding production facilities at the Seki and Kakamigahara plants and メニコンネクト.」
To expand production capacity for daily disposable lenses and care products, the company proceeded with capital expenditures at Menicon Malaysia, the Seki and Kakamigahara plants, and メニコンネクト, bringing full-year capital expenditures to ¥24,229 million. - FY2024-Q3AdvancedAnnual report
「For daily disposable contact lenses, the company began operating a new production line for 1DAY Menicon Premio at the Kakamigahara plant to meet growing domestic and overseas demand. To increase supply, the company will continue investing in an additional Magic production line at Menicon Singapore and in the construction of a new plant at Menicon Malaysia to secure future production volumes.」
A new 1DAY Menicon Premio line began operating at the Kakamigahara plant, while the addition of a Magic production line in Singapore and investment in a new plant in Malaysia continued. - FY2024-Q2AdvancedAnnual report
「Property, plant and equipment increased by ¥12,647 million from the end of the previous consolidated fiscal year to ¥87,468 million, mainly due to capital expenditures related to the construction of a daily disposable contact lens manufacturing plant at Menicon Malaysia. Cash flow from investing activities amounted to an outflow of ¥13,614 million, mainly due to capital expenditures related to the construction of the same plant.」
Construction of the Menicon Malaysia daily disposable lens manufacturing plant progressed, increasing property, plant and equipment by ¥12,647 million from the end of the previous fiscal year, while investing cash outflows for capital expenditures amounted to ¥13,614 million. - FY2024-Q1AdvancedAnnual report
「Property, plant and equipment increased by ¥8,104 million to ¥82,925 million, mainly due to capital expenditures related to the construction of a daily disposable contact lens manufacturing plant at Menicon Malaysia.」
Construction of the Menicon Malaysia daily disposable contact lens manufacturing plant progressed, increasing property, plant and equipment by ¥8,104 million through capital expenditures. - FY2023AdvancedAnnual report
「Capital expenditures for manufacturing equipment related to the construction of a manufacturing plant at Menicon Malaysia and manufacturing equipment investment at Menicon Singapore, both aimed at expanding daily disposable contact lens production capacity, as well as capital expenditures for care product manufacturing equipment at メニコンネクト」
Capacity expansion for daily disposable lenses and care products progressed, bringing capital expenditures for the fiscal year to ¥14,549 million. The company also presented a plan to allocate the ¥20,000 million in bonds issued in April 2023 to lens equipment in Malaysia and Singapore and care product equipment. - FY2023-Q3AdvancedAnnual report
「Property, plant and equipment increased by ¥6,669 million to ¥73,460 million, mainly due to capital expenditures related to the construction of a daily disposable contact lens manufacturing plant at Menicon Malaysia.」
Capital expenditures for the construction of the Menicon Malaysia daily disposable contact lens manufacturing plant progressed, increasing property, plant and equipment by ¥6,669 million. - FY2023-Q2AdvancedAnnual report
「Property, plant and equipment increased by ¥6,530 million to ¥73,320 million, mainly due to capital expenditures related to the construction of a daily disposable contact lens manufacturing plant at Menicon Malaysia. Cash flow from investing activities amounted to an outflow of ¥8,506 million, mainly due to capital expenditures related to the construction of the same plant.」
Construction of the Menicon Malaysia plant to expand daily disposable lens supply capacity progressed, increasing property, plant and equipment by ¥6,530 million, while investing cash outflows for capital expenditures amounted to ¥8,506 million. - FY2022AdvancedAnnual report
「Capital expenditures during the consolidated fiscal year were mainly directed toward expanding facilities to accommodate increased production volumes of daily disposable contact lenses and care products. Total capital expenditures for the consolidated fiscal year were ¥15,838 million, of which ¥14,438 million was in the vision care business, mainly for establishing the Menicon Malaysia plant and expanding production facilities at the Seki and Kakamigahara plants and メニコンネクト.」
Investment in the disposable lens and orthokeratology businesses funded by convertible bonds and other sources progressed, including ¥15,838 million in capital expenditures and the establishment of a plant in Malaysia. - FY2021AdvancedAnnual report
「As of the end of the consolidated fiscal year, ¥22,868 million in bonds with subscription rights to shares was recorded.」
The company issued euro-yen convertible bonds due 2025 and raised funds for disposable lens production equipment, research and development, sales sites, logistics and systems investment, and the orthokeratology business. - FY2021-Q3First statedAnnual report
「Use of funds: (1) ¥17 billion is scheduled to be allocated by March 2025 as investment funding for the disposable contact lens business. Specifically, the funds will be used for part of the company's capital expenditures to expand disposable contact lens production capacity, part of the research and development costs for disposable contact lenses, part of the investment required to strengthen domestic and overseas disposable contact lens sales sites, and part of the investment in production, logistics and sales systems. (2) ¥3 billion is scheduled to be allocated by December 2024 as investment funding for the orthokeratology lens business.」
The company newly presented an investment plan to allocate ¥17 billion from the proceeds of euro-yen convertible bonds due 2025 to the disposable lens business by March 2025 and ¥3 billion to the orthokeratology business by December 2024.